Results 241 to 250 of about 268,296 (309)

The Natural Quassinoid Brusatol Enhances Venetoclax Efficacy and Overcomes Resistance in Myeloid Leukemias

Cancer Science, EarlyView.
Schematic illustration of the mechanisms by which the natural quassinoid brusatol induces apoptosis in myeloid leukemias and enhances venetoclax efficacy via p53‐dependent apoptosis and mitochondrial dysfunction. ABSTRACT While venetoclax‐based combinations have shown promising results in acute myeloid leukemia (AML), the remission duration is ...
Shin‐ichiro Kawaguchi, Kazuya Sato, Junko Izawa, Norihito Takayama, Hiroko Hayakawa, Ken Suzaki, Susumu Goyama, Chiyoko Kato, Eiji Sakashita, Kaoru Tominaga, Hitoshi Endo, Yoshinobu Kanda   +11 more
wiley   +1 more source

Efficacy of cyclin-dependent kinase 4/6 inhibitors in preclinical adult-type ovarian granulosa cell tumor models. [PDF]

Gynecol Oncol
Brodsky AL, Welte T, Vuttaradhi VK, Yang X, Tahan E, Khlebus E, Celestino J, Powell RT, Stephan CC, Nguyen N, Geng Y, Li J, Takamatsu S, Calzoncinth K, Cobb L, Gershenson DM, Lawson B, Hillman RT.   +17 more
europepmc   +1 more source

Alpha‐B‐crystallin immunohistochemistry: A sensitive but non‐specific marker for epileptogenic lesions

Brain Pathology, EarlyView.
Ekin Güney, Ilay Caliskan, Tara Saunders, Mercedes Paredes, Calixto‐Hope Lucas, Kanish Mirchia, Rufei Lu, Merryl Terry, Erika Cagampan, Melike Pekmezci, Andrew Bollen, Arie Perry, Cathryn R. Cadwell, Tarık Tihan   +13 more
wiley   +1 more source

MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy

Cancer Science, EarlyView.
MTAP deletion creates a therapeutically actionable metabolic vulnerability through MTA accumulation and PRMT5 dependency. This review summarizes the biochemical basis of MTAP‐directed synthetic lethality, emerging PRMT5/MAT2A inhibitors, clinicogenomic features of MTAP‐deleted tumors, and future strategies for precision oncology.
Hiroaki Ikushima, Hidenori Kage
wiley   +1 more source

Retrospective review of metastatic hormone receptor-positive inflammatory breast cancer patients reveals poor responses to cyclin dependent kinase 4/6 inhibition. [PDF]

Breast Cancer Res
Nasrazadani A, Tidwell RS, Kai M, Lim B, Valero V, Tripathy D, Saleem S, Debeb BG, Lucci A, Woodward WA, Layman RM, MDACC IBC Clinic and Research Team.   +11 more
europepmc   +1 more source

Oncogenic BRAF and KRAS Promote Global DNA Hypomethylation Through a Directed Pathway That Upregulates TET3

Cancer Science, EarlyView.
Oncogenic BRAF and KRAS promote global DNA hypomethylation through a directed pathway that increases the levels of TET3, which helps drive tumorigenesis. ABSTRACT Aberrant epigenetic modification is one of the characteristics of the cancer genome.
Ichiro Onoyama, W. Rod Hardy, Shoichiro Takeishi, Lihua Julie Zhu, Yanglan Tan, Lloyd Hutchinson, Jianhong Ou, Leyuan Ma, Ching‐Man Virbasius, Masafumi Yasunaga, Keiichi I. Nakayama, Scott A. Shaffer, Michael R. Green   +12 more
wiley   +1 more source

New Assay Systems to Characterize the Broad-Spectrum Antiherpesviral and Non-Herpesviral Activity of Cyclin-Dependent Kinase (CDK) 8 Inhibitors. [PDF]

Pharmaceuticals (Basel)
Obergfäll D, Hahn F, Kicuntod J, Wangen C, Kögler M, Wagner S, Kaufer B, Marschall M.   +7 more
europepmc   +1 more source

Targeting Cell Cycle Vulnerabilities in Cancers: Emerging Strategies for Therapeutic Development

Cancer Science, EarlyView.
Dysregulated cell cycle control often involves alternative compensatory pathways in cancers to maintain its robustness but provide unique targetable vulnerabilities. We overview recent insights on cancer‐specific vulnerabilities across the cell cycle and discuss how these can be used to develop new therapeutic strategies.
Nana Kamakura, Minji Jo, Motoko Takahashi, Toru Hirota   +3 more
wiley   +1 more source

Cyclin-dependent kinase 13 is indispensable for normal mouse heart development. [PDF]

J Anat
Waheed-Ullah Q, Wilsdon A, Abbad A, Rochette S, Bu'Lock F, Saed AA, Hitz MP, Brook JD, Loughna S.   +8 more
europepmc   +1 more source

Ocular toxicity events of cyclin-dependent kinase 4/6 inhibitors in breast cancer: a pharmacovigilance study based on the faers database. [PDF]

Front Pharmacol
Zhang M, Pu D, Yu M, Shi G, Li J.
europepmc   +1 more source